Purpose We previously showed the positive effects of the new antioxidant molecule bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)-decandioate (IAC) in reducing basal hyperglycaemia and relieving glucose intolerance in a diabetes model. However, the chemical properties of IAC did not allow an efficient oral administration, thus representing the main failing of that study. Here, we tested the effect of a new oral delivery system based on solid lipid microparticles (SLMs) in a diabetes mouse model. Methods The diabetes model was induced in C57B1/6J mice using streptozotocin and nicotinamide. Only the animals that overcame the glycaemic threshold of 180 mg/dL were enrolled in the study. Diabetic animals were then randomly assigned to 4 groups (n = 9) and treated once a day for 5 consecutive weeks with IAC (50, 100, and 150 mg/kg b.w.). The control group was composed of (n = 7) healthy mice that received only the vehicle. Glucose level was weekly monitored during the treatment period and up to 3 weeks after the suspension of the treatment. Glucose tolerance and insulin-resistance test were carried out. Results Our results showed that SLMs maintained the IAC effect in reducing basal hyperglycaemia as well as improving the insulin sensitivity and glucose tolerance. Conclusion The present study confirms that SLMs are promising drug carriers, which allow the oral administration of IAC ensuring its therapeutic efficacy. The concrete possibility to administer IAC per os represents a significant breakthrough in the putative consideration of this multi-radical scavenger in the diabetes therapeutic approach.
Introduction
The World Health Organization has predicted that diabetes mellitus (DM) is going to be one of the leading causes of death by the year 2030 [1, 2] . In contrast with type 1 diabetes (T1DM), in which the autoimmune component resulting in the activation of T-cell clones against pancreatic β-cells leading to an insulin deficiency [3] , type 2 diabetes (T2DM) is mainly characterized by excessive hepatic glucose production, poor insulin secretion, and insulin resistance [4, 5] . Although there are convincing evidence that genetic conditions could play a major role in insulin resistance (IR), it is equally well-established how insulin resistance could be triggered by acquired factors such as obesity, that along with the lack of physical activity, represent some of the major risk factors for T2DM onset [6, 7] . Among the various mechanisms linking obesity to T2DM, one candidate is oxidative stress (OS) that seems to be associated with the vascular complications, as well as linked to IR, playing a central role in both aetiology and progression of the pathology [2, [8] [9] [10] . The high levels of free-radical species observed in obese IR subjects lead to protein oxidation, membrane lipid peroxidation, DNA damage, and hyperglycaemia per se [9, 11] . On the other hand, these reactive species may trigger stress-sensitive signalling pathways, such as NF-κB, with the consequent expression of pro-inflammatory factors that contribute to tissue injury [12] . Breaking the vicious cycle between OS and inflammatory response would of course be a key to success in T2DM management [13] .
For these reasons, over the past few decades, a large number of studies were focused on the potential beneficial role of antioxidants in contrasting T2DM. In particular, naturally occurring radical scavengers such as vitamin C, E, β-carotene, or phytochemicals such as flavonoids were significantly associated with a reduction of T2DM incidence as well as improving insulin sensitivity in patients [5, [14] [15] [16] [17] [18] .
We previously studied the effects of a new antioxidant molecule bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)-decandioate (IAC) in reducing in vivo and in vitro basal hyperglycaemia, improving glucose tolerance and preserving the pancreatic islets [19] [20] [21] [22] [23] . These promising results were obtained administering IAC by intraperitoneal route due to the breakage of its aliphatic chain by gastric pH. To overcome this limit, in our laboratory, we have developed a delivery system based on solid lipid microparticles (SLMs) that would allow the oral availability of IAC [24] .
The primary outcome of the study was to test the effectiveness of IAC-loaded microparticles as new delivery system in a streptozotocin (STZ) and nicotinamide (NA)-induced DM mouse model in reducing basal hyperglycaemia as well as improving the insulin sensitivity and glucose tolerance.
Materials and methods

Chemicals
IAC, nicotinamide (NA) and streptozotocin (STZ) were purchased by Sigma-Aldrich (Saint Louis, MO, USA). Human insulin (Actarapid ® -Novo Nordisk). Behenoyl polyoxyl-8 glycerides (Compritol ® HD5 ATO), kindly supplied from Gattefossè, (Milan, Italy) and stearic acid (ACEF Spa, Piacenza, Italy) were used as low melting point excipients in the manufacturing of IAC-loaded solid lipid microparticles. Colloidal silicon dioxide (Aerosil 200) was kindly supplied by Evonik Industries (Germany). All other materials and reagents were of analytical grade.
Preparation of solid lipid microparticles
Solid lipid microparticles were produced by the spray congealing technology, as described in details in the previous paper [24] . Briefly, the mixture of carriers (Stearic acid/ Compritol HD5 ATO) was heated at a temperature 10 °C above their melting point (ca. 69 °C for stearic acid and ca. 64 °C for Compritol ® HD5 ATO). IAC (18% w/w) was added to the molten carrier to obtain a liquid suspension, which was then atomised using the spray congealing apparatus equipped with a wide pneumatic nozzle (air pressure = 3.0 bar, nozzle temperature = 80 °C). The melted droplets solidified in a chamber at room temperature and formed the final SLMs, which were characterized as reported in the following paragraphs. The SLMs utilized for the in vivo experiments were then mixed with 2% w/w of colloidal silicon dioxide. The final composition of the SLMs was: Stearic acid/Compritol HD5 ATO/IAC/colloidal silicon dioxide 60/40/18/2 (% w/w).
Characterization of the microparticles
Morphology
The shape and surface characteristics of the microparticles were observed using scanning electron microscopy (SEM). Samples were sputter-coated with Au/Pd using a vacuum evaporator (Edwards, Milano, Italy) and examined using a scanning electron microscope (ESEM-FEI Quanta 200) at 20 kV accelerating voltage using the secondary electron technique.
Particle size distribution
The particle size was measured by laser diffraction using a Mastersizer 2000 (Malvern Instruments, Worcestershire, UK). SLMs were suspended in an aqueous solution containing Tween 80 (1% w/w) to allow a proper dispersion of the microparticles and to prevent agglomeration. The particle size was expressed as the volume diameter, d v (µm) in terms of d 10 , d 50, and d 90 .
Determination of drug content
A reverse phase HPLC method, developed and validated in the previous paper [24] , was utilised for the quantification of IAC. The HPLC system consisted of two mobile phase delivery pumps (LC-10ADvp, Shimadzu, Japan) and a UV-Vis detector (SPD-10Avp, Shimadzu, Japan). An autosampler (SIL-20A, Shimadzu, Japan) was used to inject samples (20 µl) onto a Kinetex 5 µm C18 column (150 mm × 4.60 mm; Phenomenex, Bologna, Italy). The mobile phase comprised of 0.02 M of potassium dihydrogen phosphate buffer with a pH adjusted at 6.6 by adding drop by drop a 1 M KOH solution and methanol (20:80, V/V). The flow rate was 1 ml/min and the detection wavelength was set at 215 nm. Retention times of Prostab were 8 min. Standard solutions were prepared by dissolving 15 mg of IAC in 20 ml of methanol. Quantitation of IAC was carried out by integration of the peak areas using the external standardization method. The level amount for IAC was analysed at least in triplicate.
The drug content in the microparticles was determined as follows: 50 mg of microparticles were accurately weighed and then added to 10 ml of methanol. The microparticle samples were then sonicated (Sonorex, Bandelin Electronics, Berlin, Germany) for 10 min and centrifuged (Costar Mini Centrifuge, USA) at 10,000 rpm for 12 min to facilitate the dissolution of the active ingredient and separate the insoluble lipid portions, respectively. Then, the drug content of the solution was assayed by HPLC. SLMs content was analysed in triplicate and the mean ± SD was reported. Finally, the encapsulation efficiency (EE) was calculated as follows:
where W a is the actual drug content and W t is the theoretical drug content.
Animal care and treatment
Induction of diabetes
Nicotinamide (210 mg/kg b.w., Sigma, Saint Louis, MO, USA) was dissolved in saline, and injected intraperitoneally (i.p.) 20 min before streptozotocin administration (180 mg/kg b.w., i.p.), and dissolved in buffer citrate (pH 4.5) immediately before use. Controls received the vehicle only (Yogurt/H 2 O 60/40%-pH 4.4). Both solutions were sterilized before injection [22] .
Experimental protocol
All efforts were made to minimize suffering. Male C57B1/6J mice aged 8-9 weeks and weighting 25 g were obtained by Harlan Laboratories S.r.l (Udine, Italy) were housed under standard conditions and they fed with regular rodent chow (18.7% crude protein, 5.6% crude fat, 4.5% crude fibre, by Mucedola s.r.l.). At the 5th and 9th days after the pharmacological induction of the pathological condition, the glycaemic index was measured through the stick glucometer (On Call Plus, ACON Laboratories, Inc. San Diego USA). Animals, which overcame the threshold of 180 mg/dL of basal blood glucose, were enrolled in the study and randomly assigned to four groups (n = 9 animals each). The randomization was performed by the use of GraphPad Software tool (La Jolla California USA).
Among these, the three groups designated to receive IAC were daily treated via gavage with a fixed volume of 200 μL at the doses of 50, 100, and 200 mg/kg b.w. for five consecutive weeks. The placebo group (n = 9) received the vehicle only (no IAC-loaded SLMs included) under the same conditions. Animals assigned to the control group (n = 7) did not received the treatment with STZ-NA (non-diabetic mice), but followed the same procedure described above for the placebo group, see Table 1 for the time line of the experiment.
Body weight and water consumption
Animals weight and water consumption were monitored weekly.
Glycaemia monitoring
Animals were kept fasted for 3 h before the test. Blood was collected from the tail vein. Values were recorded by the use of the stick glucometer. The procedure was repeated once a week during the treatment period and up to 3 weeks after the last administration of IAC.
Glucose tolerance test
After 4 weeks of IAC treatment, glucose (1.5 g/kg b.w. as 16.5% solution) was administered i.p. to 3 h fasting 
Insulin-resistance test
After 5 weeks of pharmacological treatment, 3 h fasting animals were injected intraperitoneally with 75 IU of human insulin. The glucose measurement checkpoints were scheduled at T0 (before injection) and at 15, 60, 120, and 180 min after the insulin delivery.
Statistical analysis
Results are expressed as mean ± standard error of the mean (SEM). Statistical analysis was performed using the ANOVA corrected for multiple comparison using Sidak-Bonferroni method. A p value < 0.05 was considered significant.
Results and discussion
In the last decades, accumulating evidence has recognized OS as a common denominator in many metabolic disorders including DM and its related comorbidities [25, 26] . When hyperglycaemia occurs, the higher glycolytic flux and pyruvate, feeding the tricarboxylic acid cycle, lead mitochondria to enhance the production of reactive oxygen species (ROS) and pancreatic cell are particularly prone to oxidative damage resulting in cell failure and insulin deficiency [6, 22, 23, 27] . In addition, OS has been suggested to be associated to aberrant insulin signalling in target tissues, by activating the Values are expressed as mean ± SEM of 7-9 animals for each group. *p < 0.05, **p < 0.01, significant differences between control/treated groups and placebo groups, using the ANOVA corrected for multiple comparison using Sidak-Bonferroni method inflammation response in pancreatic islets as well as other mechanisms [26, 28] . Based on these considerations, the preservation of the oxidative homeostasis by the use of antioxidants has been suggested to be a valid aid in DM therapy schedule [13, 29] .
The bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)-decandioate (IAC) (Fig. 1) was recently found to attenuate diseases, where OS has a pathophysiological role [23, [30] [31] [32] . Moreover, unlike conventional antioxidants, IAC has an additional action: upon quenching ROS, it becomes super-activated, turning from a hydroxylamine to a nitroxide-an even more potent and catalytic antioxidant [33] . IAC is structurally related to TEMPOL, a nitroxide radical able to attenuate diabetes-induced lactate generation improving the lactate-to-pyruvate ratio [34] . The long aliphatic chain connecting the two cyclic hydroxylamine moieties (Fig. 1 ) confers to IAC a higher membrane permeability. [30] . Although the idea that IAC could be a beneficial complement in DM management was supported by both in vitro and in vivo studies [19, 20, 22] , we were denied to access to the oral route of administration, due to the IAC chemical nature.
In the last years, our efforts were focused on the development of a successful delivery system to overcame this limit. In our previous paper [24] , we have investigated the potential of solid lipid microparticles as IAC carrier that allowed the oral administration of IAC while maintaining its efficacy. IAC-loaded SLMs have been produced using the spray congealing technique. The results demonstrated that the spray congealing process was suitable to produce IAC-loaded microparticles with no chemical degradation of IAC [24] ; therefore, in the present paper, IAC-loaded SLMs have been produced using the same process parameters and characterized as regards morphology, particle size, and actual IAC content. Figure 2 demonstrates that, as expected, non-aggregated microparticles with a regular and spherical shape and smooth surface without imperfection were obtained. Particle size analysis data showed that SLMs Values are expressed as mean ± SEM of 7-9 animals for each group. *p < 0.05, **p < 0.01, significant differences between control/treated groups and placebo groups, using the ANOVA corrected for multiple comparison using Sidak-Bonferroni method were characterized by a mean diameter (d 50 ) of 192.35 µm, while d 10 and d 90 were 78.94 and 335.2 µm, respectively; these dimensions were ideal for filling hard capsules to be administered by the oral route. The actual IAC content of the microparticles was 17.35 ± 0.62%, very close to the theoretical value (18% w/w), resulting in an encapsulation efficiency of 96.4%. Therefore, the technological characteristics of the new batch of SLMs were very similar to the previous formulation B ones [24] , demonstrating that the spray congealing is a robust process for the production of IAC-loaded SLMs
As it can be seen in Fig. 3a, b , IAC was effective in reducing glycaemia (p < 0.05) at the 1st week of treatment; notably, the results recorded at the last check point during the 5th week of the protocol showed glucose values comparable with those reported by the control group (Fig. 3b) . These data are of particular interest considering that it was reported that the oral administration of 100 mg/kg b.w. of metformin to STZ-induced diabetic rats, yielded a glucose-lowering activity of around 21% [35] , comparable with that obtained with IAC given at 100 or 200 mg/kg b.w. Noteworthy, the hypoglycaemic effect persisted after the treatment was ended. In particular, during the 1st week after IAC suspension, all the groups maintained the levels of blood glucose lower (p < 0.05) with respect of the placebo group (Fig. 3c,  d ). Furthermore, 2 weeks after IAC withdrawal, in the highest dose group, the IAC effect was still present with a variation resulted virtually nil (≈ 23% reduction; p < 0.05), and hence, we demonstrated that our delivery system (SLMs) allows the oral route while keeping IAC effective and bioavailable that was the major challenge of the present study.
The post-loading blood glucose profile and insulin sensitivity (Figs. 4a, 5a) were significantly improved after the treatment with 100 or 200 mg/kg b.w. (p < 0.01; p < 0.05) as confirmed by the AUCs represented in Figs. 4b and 5b .
Data on bodyweight (Fig. 6a, b) did not show a drop among the animals of placebo group as expected. Usually, streptozotocin leads to a ponderal decrement; however, the pre-treatment with nicotinamide can attenuate the weight fall as well as other physiological changes [36, 37] .
Based on our previous experience, we would have expected to observe a decrease in body weight among the animals of placebo group. The growing curves (Fig. 6a, b) Fig. 5 Insulin sensitivity test in control and IAC-treated diabetic mice. a Glycaemia improves at all the tested dosages. b Area under the curve (AUC) graph shows the significant (p < 0.05) reduction of the insulin intolerance in each treated group with respect to the placebo group. Values are expressed as mean ± SEM of 7-9 animals for each group. *p < 0.05, **p < 0.01, significant differences between control/treated groups and placebo groups, using the ANOVA two-tailed unpaired t test corrected for multiple comparison using Sidak-Bonferroni method Fig. 6 Metabolic parameters. a Growing curves indicates a significant (p < 0.01) decrement of body weight at the highest dose. b IAC 100 and 200 mg/kg b.w. causes a significant body weight loss. c IAC treatment significantly reduces water consumption in treated groups with respect to placebo. Values are expressed as mean ± SEM of 7-9 animals for each group. *p < 0.05, **p < 0.01, significant differences between control/treated groups and placebo groups, using the ANOVA twotailed unpaired t test corrected for multiple comparison using Sidak-Bonferroni method did not confirm the our hypothesis indicated a decrement of body weight at the highest dose, no significantly decline raised from the analysis of the body weight gain between the start point and the 5th week of treatment (Fig. 6b ). Our DM model presented the polydipsia condition [38] compared to controls ( Fig. 6c ; p < 0.01), and as it can be noted, IAC has relieved this symptom (p < 0.05).
Conclusions
Despite often antioxidants have been overhyped as compared to their real human efficacy, we are confident that our results being based on innovative molecular properties, and will encourage the launch of further studies on this promising new antioxidant. As a whole, our data indicate that the IAC-loading particle technique developed by us has been proven to be a promising drug carrier ensuring IAC antidiabetic action. The concrete possibility to orally deliver the molecule represents a decisive step forward for a putative future clinical trial for testing this new antioxidant. In a broader sense, our findings reinforce the notion that antioxidant agents such as IAC could play a prominent role in diabetes and they could be considered in future clinical trials and therapeutic plans.
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